Transglutaminase 6

Human neuronal transglutaminase


(TG6, recombinantly produced in insect cells)

Order
Quantity
Price
Status
250 µg 475 € available


Documents
Art. No. T021
Synonym Neuronal Transglutaminase, TGy, TG6, TGase 6, protein-glutamine-γ-glutamyltransferase

neuronal transglutaminase TG6 T021 by Zedira
Molecular Weight 78 kDa
Source Recombinantly produced in insect cells
Purity > 95% [SDS-PAGE and Coomassie staining]
Activation His6-rhTG6 is a Ca2+-dependent enzyme.
Appearance White lyophilized solid.
Reagents The Transglutaminase is lyophilized from 10 mM Tris-HCl pH 8.2, 500 mM NaCl, 2 mM DTT. Sample contains sucrose.
Reconstitution Add the volume of water specified in the certificate of analysis under aliquotation to the vial of lyophilized powder. Rotate vial gently until solid dissolves. After reconstitution the solution should be stored frozen in working aliquots. For short term storage keep cooled on ice.
Application His6-rhTG6 catalyzes acyl transfer reactions from glutamine residues in proteins or peptides to primary amines, e. g. the formation of ε-(γ-glutamyl) lysine bonds between proteins by transferring the acyl group of a peptide-bound glutamine residue to the primary amino group of a peptide-bound lysine residue.
Storage T021 is stable for at least one year if stored at ≤ -20°C.
Avoid freeze-thaw cycles.
Reference(s) Fukui et al., FEBS J. 2013, 280:1420-9
Schaertl et al., J. Biomol. Screen. 2010, 15:478-87
Note Intended for research use only, not for use in human, therapeutic or diagnostic applications.

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • Zedira supports Gordon Research Conference
  • imagePress release: Zedira announces ISO 9001:2015 certification
  • imageZedira communication: Joint poster presentation on “Feasibility of a new automated FXIII activity assay”
  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
  • imagePreview: Catalogue Editorial 2019
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation

Blog  

Events  

  • World ADC London 2020

    02.03.2020 - 05.03.2020
    London, Great Britain

  • Celiac Disease Center's International Symposium

    06.03.2020 - 07.03.2020
    New York, USA

  • Gordon Research Conference - Transglutaminases in Human Disease Processes

    14.06.2020 - 19.06.2020
    Mount Snow, USA

  • Tampere Celiac Disease Symposium 2020

    18.09.2020 - 19.09.2020
    Tampere, Finland

  • 19th International Celiac Disease Symposium

    30.09.2021 - 03.10.2021
    Sorrento, Italy